CD22 and systemic lupus erythematosus: DN2 cells from SLE patients have the ability to signal through the BCR despite expressing CD22 and FCRL5 inhibitory receptors (9), however the functional capacity of DN2 cells to respond to BCR signaling in healthy individuals or other disease states has not been reported.